Trial Profile
A multicenter controlled phase II clinical study on oral administration of amlotinib after first-line treatment of ovarian cancer
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 04 Jul 2018
Price :
$35
*
At a glance
- Drugs Catequentinib (Primary)
- Indications Ovarian cancer
- Focus Therapeutic Use
- 04 Jul 2018 New trial record